



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

AUG 27 2002

RECEIVED

In re patent application of:

Grouzmann, *et al.*

Appl. No.: 09/993,959

Filed: November 27, 2001

For: **Method of Treating Rhinitis or Sinusitis**

Group Art Unit: 1651

Examiner: M. Meller

Atty. Dkt.: 7571/73191
(formerly 81985/282428)

Response to Restriction Requirement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated July 30, 2002, in which the Examiner imposed a restriction requirement on the above-captioned application, Applicants hereby elect the inventions of Restriction Group I. This includes claims 9-15, directed to therapeutic packages. It is respectfully requested that claim 16 in non-elected Restriction Group II be cancelled.

The Examiner has required that, upon the election of Restriction Group I, Applicants must elect a specific species of enzyme for consideration during prosecution. In compliance with this requirement, Applicants hereby select dipeptidyl peptidase IV. The present claims that read on this species are claims 9, 10 and 11.

This election is made without traverse.

Applicants do not believe that any fees, other than those that may be already provided for herewith, are required for the filing of the present document. Nevertheless, any additional fees that may be required may be charged to our Deposit Account No. 06-1135.

If the Examiner believes that a phone call may help to expedite this matter, the Examiner is invited to call Applicants' undersigned attorney at (202) 419-7013.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By: Michael A. Sanzo

Michael A. Sanzo

Reg. No. 36,912

Attorney for Applicants

Date: August 23, 2002
1801 K Street, NW, Suite 401L
Washington, DC 20006
(202) 419-7013